$THRY

Thryv Holdings, Inc. Q1 2026 Financial Results and Risk Factors – Form 10-Q Highlights

Thryv Holdings, Inc. (THRY) reported a return to profitability in Q1 2026, with a net income of $4.5 million and basic EPS of $0.10, a significant improvement from the previous year's net loss. Total assets and stockholders' equity also increased, reflecting a strengthening financial position. However, the company disclosed an SEC investigation, introducing regulatory uncertainty that could impact its financial position and share value.

Original reporting
Published May 1, 2026, 4:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 1, 2026, 5:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Thryv Holdings, Inc. Q1 2026 Financial Results and Risk Factors – Form 10-Q Highlights — source image
Decision brief

The 30-second read

$THRYNeutralMed
01

Why it matters

The positive earnings report may boost investor confidence temporarily, but the SEC investigation could lead to increased volatility and potential negative impacts if regulatory actions are taken.

02

Market read

The news is relevant for traders and investors focused on small-cap technology and financial services sectors, with immediate implications for THRY stock and related assets.

03

What to watch

Potential macroeconomic shifts or industry-specific trends that could influence the company's future performance are not addressed here.

Timing: Immediate, as the news is recent and impacts current trading sessions.

Background

Thryv Holdings, Inc. reported a return to profitability in Q1 2026, driven by operational improvements and increased assets. The company disclosed an SEC investigation, which introduces regulatory uncertainty.

Company-level read

Ticker impact

$THRYNeutralMedium confidence
Context

The company's Q1 2026 financial results show a return to profitability, which is positive for shareholders. However, an SEC investigation introduces regulatory uncertainty.

Expected impact

Moderate positive impact in the short term due to improved earnings; potential volatility if SEC investigation leads to regulatory actions.

Evidence & confidence

Financial improvements are clear, but regulatory uncertainty could offset gains, leading to mixed market reactions.

Market effects

The financial sector may experience slight positive sentiment due to improved earnings reports across similar companies, but regulatory concerns could dampen enthusiasm.

Limited regional impact; primarily affecting investors and markets with exposure to Thryv Holdings.

Minimal, as the company's size and market influence are relatively contained.

Counterpoint

The SEC investigation could lead to significant penalties or operational disruptions, making the recent earnings rebound less sustainable.

Key entities

  • Thryv Holdings, Inc.

    A provider of small business management software and marketing solutions.

  • SEC

    The U.S. Securities and Exchange Commission, overseeing securities markets and enforcing federal securities laws.

Related articles

$THRYHighAI 9/10

Why is Thryv stock plunging today?

Thryv Holdings Inc shares fell 35.6% to $2.75 after the company reported Q2 2026 results before the open. Thryv posted an adjusted loss of $0.38 per share versus a $0.10 consensus and revenue of $150.7 million versus about $146 million. The company also cut full-year SaaS guidance and announced $55-60 million annualized cost savings.

$THRYMed

Thryv Holdings, Inc. (THRY): Results of Operations and Financial Condition

Thryv Holdings, Inc. (THRY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Thryv Reports Second Quarter 2026 Results and Launches Thryv Growth Platform – Q2 SaaS Revenue Grows to 76% of Total Revenue – Q2 SaaS Monthly ARPU Increases 12% Year-Over-Year to $394 – Company Announces Strategic Restructuring Plan to Improve Operating Efficiencies

$VRTXMedAI 8/10

Inaxaplin Shows Kidney Benefit In Additional Patient Groups As Vertex Completes Key Trial Enrollment

Vertex Pharmaceuticals (VRTX) reported positive Phase 2b results for Inaxaplin in additional patient groups with APOL1-mediated kidney disease, showing reductions in kidney damage markers. The company completed enrollment in its Phase 2/3 AMPLITUDE trial, with interim results expected in early 2027. Inaxaplin was generally safe and well-tolerated. VRTX stock is up 2.88% at $525.18.